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required during the early reperfusion phase to reduce myo-
cardial infarct size. This suggests that strategies specifically 
enhancing the α isoform of PI3K at reperfusion promote 
tissue salvage and as such, and could provide a direct target 
for clinical treatment of IRI.
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Introduction
Ischemic preconditioning (IPC), whereby brief cycles of 
non-lethal ischemia and reperfusion protect the myocar-
dium from a subsequent, sustained ischemic insult, was first 
described by Murry et al. in a canine model in 1986 [35]. 
Over the last three decades, IPC has been reproduced in all 
species examined [54], including humans [53], and has also 
been replicated in other organs when applied either locally 
or remotely [18]. The underlying mechanisms of IPC have 
been largely uncovered and subsequently extrapolated to 
most cardioprotective therapies [13]. IPC has indeed become 
the paradigm for cardioprotection, although its signalling 
architecture is still the subject of intense research aimed to 
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identify novel therapeutic targets to treat ischemia/reperfu-
sion injury (IRI).
IPC signal transduction is understood to be mediated 
by a three-step process [16]: (1) the release of triggers that 
usually bind sarcolemmal membrane receptors (e.g., brady-
kinin); (2) the activation of intracellular mediators (signal-
ling cascades that help initiate and propagate the signal, i.e., 
pro-survival kinases); and (3) the action of an end-effector 
that attenuates cell injury, i.e., inhibition of mitochondrial 
permeability transition pore (mPTP).
The IPC-induced protective effect is mediated by pro-
survival signalling cascades, such as the Reperfusion Injury 
Salvage Kinase (RISK) pathway, the Survivor Activator Fac-
tor Enhancement (SAFE), and the NO/PKG pathway [9, 16, 
26, 29]. The RISK pathway encompasses the activation of 
two parallel kinases (PI3K and ERK1/2) [14, 54]. PI3K has 
been demonstrated to play a dominant role within the RISK 
pathway [12, 40], with insights into its role in mediating IPC 
protection having been revealed by the use of pan-specific 
PI3K inhibitors, such as wortmannin and LY294002 [13]. 
In recent years, isoform-specific PI3K inhibitors have been 
developed in the field of oncology [51], but these have not 
yet been explored in the context of myocardial infarction, 
studies which could aid in the development of PI3K isoform-
specific agents thereby further enhancing cardioprotection.
PI3Kα has emerged as a key player in cardiac physiology, 
improving contractility [30, 52], and promoting physiologi-
cal exercise-induced growth, but not pathological hypertro-
phy [33]. Constitutively active PI3Kα has also been demon-
strated to improve left ventricular function in a heart failure 
model [28]. Using broad-spectrum PI3K inhibitors, insulin 
has proven to be cardioprotective through the activation of 
PI3K [22]. Based on the notion that insulin has been shown 
to be a canonical activator of PI3Kα [8, 27], we hypoth-
esized that PI3Kα may play a central role in cardioprotec-
tion. We, therefore, studied the importance of PI3Kα either 
using PI3Kα-selective inhibitors and/or enhancing PI3Kα 
activity using insulin, or by delaying the opening of its end-
effector mPTP through PI3Kα inhibition. The dissection 
of this signalling pathway could help develop co-adjuvant 
interventions which, when added to reperfusion therapy, 
would further protect the heart against myocardial IRI in 
patients with an acute myocardial infarction.
Methods
Animals and chemicals
Animals used were male C57BL/6 mice (9–12  weeks, 
24–28 g weight), obtained pathogen free from a single sup-
plier and housed under identical conditions.
BYL719 (Alpelisib) was purchased from Selleck Chemi-
cals. GDC–G326 was obtained from Genentech. Human 
insulin solution was purchased from Sigma-Aldrich. Dime-
thyl sulfoxide (DMSO, BDH laboratory supplies, UK) was 
used as the solvent for BYL719 and GDC–G326 at a final 
concentration not higher than 0.01%.
Both GDC–G326 and BYL719 are potent and highly 
selective PI3Kα inhibitors [5, 15, 48]; their dosage being 
established based on the previous publications [5, 48] and 
in a dose–response characterization study in this paper (see 
“Results” section). Insulin was tested as a canonical activa-
tor of PI3Kα [8, 27] and used at two doses: 100 mU/mL to 
characterize PI3Kα inhibitors and 5 mU/mL as a low dose 
with known cardioprotective properties [1, 23].
Experimental design and study protocols
Outlines for most study protocols can be found through the 
figures, as well as in the supplemental material (Supple-
mental Figures 1–5). Additional protocols were as follows:
1. PI3Kα protein levels aimed to characterize and quantify 
the expression under basal conditions of this PI3K iso-
form in both primary adult mouse cardiomyocytes and 
mouse cardiac endothelial cells (MCECs), as well as in 
mouse and human heart tissue (n = 5 per group).
2. IPC protocol selection Langendorff-perfused adult mice 
hearts were randomized into three groups (control, IPC 
1 cycle, and IPC 4 cycles) to determine differences in 
myocardial infarct size and Akt activation.
3. PI3Kα inhibitor dose selection aimed to determine the 
dose of PI3Kα inhibitors against the canonical activator 
PI3Kα insulin, using Akt as a surrogate for PI3K activa-
tion and inhibition in line with published data [21, 31, 
32, 50].
4. PI3Kα inhibition to abolish the IPC-induced cardiopro-
tective effect (ex vivo) aimed to determine the role of 
PI3Kα as IPC mediator in the ex vivo Langendorff-per-
fused mouse model, where hearts subjected to 35 min 
ischemia and 2 h reperfusion [39] received either GDC–
G326 or BYL719 during the IPC protocol (which con-
sisted of 4 cycles of 5 min ischemia and 5 min reperfu-
sion), or at reperfusion. Both myocardial infarct size and 
Akt phosphorylation were assessed separately for each 
set of experiments.
5. PI3Kα inhibition to block the IPC-induced cardiopro-
tective effect (in vivo) We used an in vivo mouse model 
of myocardial infarction (40 min ischemia and 120 min 
reperfusion) subjected to an IPC protocol, in the pres-
ence or absence of the PI3Kα inhibitor GDC–G326, 
administered through external jugular vein at reperfu-
sion.
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6. PI3Kα activation at reperfusion (ex vivo) aimed to 
assess whether the administration of the PI3Kα canoni-
cal activator (insulin) is sufficient to elicit cardioprotec-
tion and whether this effect can be abolished through 
PI3Kα inhibition. Both myocardial infarct size and Akt 
phosphorylation were evaluated.
7. PI3Kα activation in cardiomyocytes and MCECs aimed 
to study whether both cell types could potentially be 
involved in the activation of the PI3Kα pathway (Akt 
phosphorylation was evaluated).
8. PI3Kα translational ability aimed to evaluate whether 
PI3Kα activation, through its canonical activator 
in human tissue, can be comparable to the outcome 
observed in mouse tissue (Akt phosphorylation was 
evaluated).
9. Impact of PI3Kα activation on the end-effector mPTP, 
aimed to evaluate whether PI3Kα activation delays 
mPTP opening (hence delaying cell death) using insu-
lin as a canonical PI3Kα activator and the GDC–G326 
inhibitor. The outcome was measured as half time to 
mPTP opening.
Ex vivo isolated Langendorff‑perfused mouse heart 
model of acute myocardial infarction
Heart isolation and Langendorff perfusion were carried out 
with filtered modified Krebs–Henseleit buffer (composed of 
118 mM NaCl, 25 mM  NaHCO3, 11 mM glucose, 4.7 mM 
KCl, 1.22  mM  MgSO4·7H2O, 1.21  mM  KH2PO4, and 
1.84 mM  CaCl2·2H2O) aerated with a mixture of  O2 (95%) 
and  CO2 (5%) to uphold pH at 7.40 ± 0.3, as previously 
described [39]. Briefly, mice were given terminal anesthe-
sia and anticoagulation through an intraperitoneal injection 
of 60 mg/kg sodium pentobarbitone and 100 IU heparin, 
respectively. Hearts were then harvested, submerged in ice-
cold modified Krebs–Henseleit buffer, and immediately can-
nulated with a 21-gauge cannula to be retrogradely perfused 
on a murine Langendorff perfusion apparatus at 80 mm Hg 
pressure.
Predefined exclusion criteria were as follows: (1) more 
than 4 min time between heart removal and the start of per-
fusion in the Langendorff mode; (2) temperature above or 
below the 37 + 0.5 °C range; and (3) buffer flow rate of the 
isolated heart of less than 1 mL/min or more than 6.5 mL/
min on the Langendorff preparation during the stabilization 
period. After evaluating for exclusion criteria in an initial 
20 min stabilization period, the hearts were subjected to 
experimental protocols of: (a) perfusion for 30 min to col-
lect heart tissue and study the protein expression of PI3Kα 
under basal conditions; (b) IRI in the presence of IPC, drug, 
and/or vehicle, as indicated in each protocol (see Fig. 3a, c; 
Supplemental Figures 1 and 4); and (c) Akt phosphorylation 
following a given intervention, such as IPC and/or PI3Kα 
activation and inhibition (see Fig. 4a; Supplemental Fig-
ures 2, 3, and 5).
In vivo murine model of acute myocardial infarction
C57Bl/6 mice were anaesthetized by intraperitoneal injec-
tion of 80 mg/kg pentobarbitone at a concentration of 20 mg/
mL in 0.9% (w/v) saline and maintained at 36.5 ± 0.5 °C on 
a heating mat. Surgery was started after confirming the abol-
ishment of pedal and tail reflexes. Mice were intubated using 
a 19G cannula and ventilated with room air using a Mini-
Vent, type 845, Small Animal Ventilator (Harvard Appa-
ratus, Kent, UK), at a flow rate of 1.0 l/min with 2 cmH2O 
PEEP, stroke volume 200 μl at 130 strokes/min. All mice 
were subjected to occlusion of the left anterior descending 
(LAD) for 40 min, which was verified by ST elevation in the 
electrocardiogram and by the presence of hypokinesia and 
pallor in the heart, followed by 2 h reperfusion. After the 
protocol finished, animals were killed by exsanguination via 
the thoracic aorta. Afterwards, myocardial IS was measured 
as described in the next section. A total of 33 mice were 
used for infarct experiments and were randomly assigned to 
treatment group. Seven mice died during the procedure and 
were, therefore, excluded from analyses (three in control 
group, three in IPC, and one in IPC + GDC–G326); hence, 
each group included six animals.
Mice were randomized to the following groups: (1) con-
trol; (2) IPC; (3) IPC and GDC–G326 at reperfusion; and (4) 
GDC–G326 at reperfusion (see Fig. 3d for further details). 
IPC was induced by applying 3 cycles of 5 min ischemia and 
5 min reperfusion in the LAD. Vehicle control and IPC mice 
received 50 μl of 6% DMSO in saline (vehicle). GDC–G326 
was dissolved in DMSO and injected via external jugular 
vein (6 μg per ~ 25 g mouse) at reperfusion in groups 3 
and 4.
Myocardial infarct size analysis
At the end of the protocol, the heart was either removed from 
the Langendorff rig (ex vivo experiments) or else isolated 
from the animal and aortic root cannulated (in vivo experi-
ments, and 5 mL of 1% 2,3,5-triphenyltetrazolium chloride 
(TTC) in phosphate-buffered saline injected through the 
aortic cannula and incubated for 10 min at 37 °C to demar-
cate the infarcted (white) vs. viable (red) tissue [25]. For 
regional IRI experiments, the LAD coronary artery was then 
re-ligated to perfuse Evans blue dye (2 mL of 0.5%) to delin-
eate the area at risk (AAR).
After the incubation, hearts were frozen overnight at 
− 20 °C and sectioned perpendicular to the long axis the day 
after, being the slices transferred into 10% neutral formalin 
buffer for 1 h at room temperature. Images were taken and 
coded to blind the analyzer. Planimetry analysis using Image 
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J version 1.47 (NIH, Bethesda, MD, USA) was carried out to 
quantify myocardial IS as a percentage of the AAR.
Human atrial tissue acquirement
Human atrial tissues were collected from Barts Heart Cen-
tre at St Bartholomew’s Hospital. The study received Local 
Research Ethics Committee approval (REC No. 00/0275) 
and was carried out in accordance with the University Col-
lege London Hospitals NHS Trust guidelines. All patients 
were provided with a Patient Information Sheet and a verbal 
explanation of the study, in line with Good Clinical Practice 
guidelines. All patients provided written informed consent 
and were free to participate in the Barts Cardiovascular 
Registry.
All patients were aged 18–80 years and their baseline 
characteristics were recorded upon consent. Patients with 
impaired renal or ventricular function, dilated left atria, or a 
history of arrhythmias or on rhythm stabilising medications 
were excluded. Patients with arrhythmias were excluded 
based on a previous publication demonstrating that PI3K 
activation in atrial appendages from patients with atrial 
fibrillation was lower compared with tissue from patients 
in sinus rhythm [37].
Right atrial appendage samples were harvested from 
patients undergoing cannulation for cardiopulmonary bypass 
either for coronary artery bypass graft or valve replacement. 
Once the cardiac surgeon provided the atrial tissue, sam-
ples were placed in ice-cold, oxygenated modified Tyrode’s 
buffer (NaCl 118.5 mM, KCL 4.8 mM,  NaHCO3 24.8 mM, 
 KH2PO4 1.2 mM,  MgSO4·7H2O 1.44 mM,  CaCl2·2H2O 
1.8 mM, glucose 10.0 mM, pyruvic acid 10 mM, pH 7.4) 
and transferred promptly to The Hatter Cardiovascular Insti-
tute at University College London.
Right atrial appendage samples were used for both assess-
ing the basal protein expression of PI3Kα and undertaking 
a pharmacologic approach with both PI3Kα activator and 
inhibitor.
Experimental protocol for adult mouse ventricular 
cardiomyocyte isolation
Adult mouse ventricular cardiomyocytes were isolated using 
liberase heart digestion as described previously [38]. Briefly, 
hearts were excised and cannulated through the aorta before 
retrograde perfusion on a murine Langendorff apparatus at 
37 °C. Following perfusion with buffer (consisted of NaCl 
113 mM, KCl 4.7 mM,  KH2PO4 0.6 mM,  Na2HPO4 0.6 mM, 
 MgSO4·7H2O 1.2 mM,  NaHCO3 12 mM,  KHCO3 10 mM, 
Hepes Na salt 0.922 mM, Taurine 30 mM, 2,3-butanedione-
monoxime 10 mM and glucose 5.5 mM) for 5 min to clear 
residual blood, and enzymatic digestion was performed 
using 30 mL perfusion buffer with 5 mg Liberase (Roche, 
UK) and 12.5 μmol/L  CaCl2 for about 20 min. At the end 
of enzymatic digestion, both ventricles were isolated and 
mechanically disaggregated in a gentle manner. The result-
ing cell suspension was filtered through a mesh and trans-
ferred for enzymatic inactivation to a tube with 10 mL of 
stopping buffer (perfusion buffer supplemented with fetal 
bovine serum 10%), and  Ca2+ was gradually re-introduced 
with a three-step increasing  CaCl2 concentration. Cells were 
then re-suspended in M199 (Invitrogen, UK) supplemented 
with l-carnitine (2 mM), creatine (5 mM), taurine (5 mM), 
penicillin (100 IU/mL), streptomycin (100 IU/mL), and 
25 μmol/L blebbistatin.
Cell culture
Immortalized mouse cardiac endothelial cell (MCEC) 
is derived from microvascular neonatal mouse cardiac 
endothelial cells.
MCECs were cultured with Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10% fetal bovine 
serum at 80–90% confluence. The cells were kept in an incu-
bator at 37 °C, with 95%  O2 and 5%  CO2.
MCECs were used to quantify the protein levels of PI3Kα 
as well as to study their response to the pharmacological 
activation and inhibition of PI3Kα.
Tissue homogenates
Mouse hearts and human atrial tissues were obtained as 
previously described. Tissue samples were swiftly snap-
frozen in liquid nitrogen after being collected and then 
stored at − 80 °C until further processing. The tissue was 
homogenized in protein lysis buffer, containing Tris pH 
6.8 (100 nM), NaCl (300 mM), NP40 0.5%, Halt protease 
inhibitor cocktail, Halt phosphatase inhibitor cocktail, and 
0.5 M EDTA (all from Thermo Scientific, UK) and adjusted 
to pH 7.4. Homogenates were then sonicated before being 
centrifuged at 4 °C to remove the pellet containing debris 
and DNA.
Western blot analyses
To ensure equal sample loading, protein concentration was 
determined using bicinchoninic acid (BCA) protein assay 
reagent (Sigma, UK) and adjusted accordingly. NuPAGE 
LDS Sample Buffer (4X) (Thermofisher Scientific, UK) 
plus 5% β-mercaptoethanol were added to the samples, 
which were subsequently denatured by heating to 100 °C 
for 10 min. Samples were then loaded on NuPAGE Novex 
10% Bis–Tris protein gels (Thermofisher scientific, UK) 
using the Mini Protean III system (Bio-Rad, UK). Proteins 
were transferred onto nitrocellulose blotting membrane 
(GE Healthcare Life Sciences, UK) through wet transfer in 
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a Bio-Rad Mini Trans-Blot. The membranes were blocked 
for 1 h using 5% bovine serum albumin/PBS tween and sub-
sequently incubated with appropriate primary antibodies at 
4 °C overnight.
The following primary antibodies being used were 
acquired from Cell Signalling Technology: Akt (#9272), 
Phospho-Akt (Ser473) (#9271), Phospho-Akt (Thr308) 
(#2965), and PI3 Kinase p110α (#4249). Anti-GAPDH 
(mAbcam, #9484) was used as loading control. After over-
night incubation, membranes were probed with secondary 
antibodies. Levels of protein were finally quantified using 
the Odyssey imaging system from Li-Cor Biosciences 
(Image Studio Lite Ver 5.2).
Basal PI3Kα protein expression
Expression of PI3Kα protein levels was evaluated by west-
ern blot analyses in mouse heart and human atrial tissues, 
as well as primary adult ventricular mouse cardiomyocytes 
and MCECs line.
To quantify protein expression, three different amounts 
of recombinant PI3Kα protein (1, 3, and 10 ng, PI3Kα from 
Merck Millipore) were loaded in the gels alongside the sam-
ples of interest. After being transferred, membranes were 
probed with specific primary antibodies for PI3Kα. For each 
membrane, PI3Kα values were extrapolated using a lineal 
regression. Results were expressed as ng of PI3Kα per μg 
of heart protein.
Basal PI3Kα mRNA expression
Mouse hearts were removed and perfused with PBS to 
remove the blood and then formalin-fixed, paraffin-embed-
ded, and sectioned.
RNAscope (ACD Bio) was performed according to the 
manufacturer’s methods. Briefly, slides were deparaffinised 
for 10 min in Histoclear and then dried in 100% alcohol. 
Slides were incubated in hydrogen peroxide for 10 min RT, 
and then washed in distilled water. Antigen retrieval was 
performed by heating for 15 min at 100 °C in target retrieval 
reagent, then incubating for 30 min at 40 °C in protease plus. 
Next, the tissue section was hybridized with the  RNAscope® 
Mm-Pik3ca Probe (catalogue number 313581), for 2 h at 
40 °C, washed, and fluorescence developed using the Perkin 
Elmer TSA plus fluorescein kit. The slides were then coun-
terstained with DAPI to stain nuclei, mounted overnight, 
and sequentially imaged using the 405 nm (for DAPI) and 
488 nm laser lines of a Leica confocal microscope and emis-
sion filters of 410–480 and 495–550 nm. Positive control 
slides using the positive control probes supplied in the kit, 
and negative controls in the absence of hybridization probe 
were performed in parallel.
Pharmacologic activation and inhibition of PI3Kα 
in cells and tissues
Akt phosphorylation was evaluated by western blot anal-
yses after the pharmacologic activation and inhibition of 
PI3Kα in tissues (mouse heart and human atrial tissues) and 
cells (primary adult ventricular mouse cardiomyocytes and 
MCECs).
Prior to being subjected to the pharmacologic stimulation, 
MCECs were deprived of serum for 2 h. Both cell types 
were incubated for 15 min according to the following inter-
ventions: (1) vehicle control (0.01% DMSO); (2) Insulin 
(5 mUl/mL); (3) Insulin 5 mUl/mL with 30 min pretreatment 
GDC–G326 3 μM; and (4) GDC–G326 3 μM.
Mouse Langendorff-perfused hearts were stabilized for 
20 min and then perfused for 15 min with: (1) vehicle con-
trol (DMSO) perfusion; (2) Insulin (5 mUl/mL); (3) Insulin 
5 mUl/mL and GDC–G326 3 μM; and (4) GDC–G326 3 μM.
After being collected in the theatre, human atrial tis-
sue was dissected in four pieces and swiftly submerged 
in previously oxygenated Tyrode’s modified buffer (NaCl 
118.5 mM, KCL 4.8 mM,  NaHCO3 24.8 mM,  KH2PO4 
1.2 mM,  MgSO4·7H2O 1.44 mM,  CaCl2·2H2O 1.8 mM, glu-
cose 10.0 mM, pyruvic acid 10 mM, pH 7.4) for 30 min in 
the presence of: (1) vehicle control (DMSO); (2) Insulin (5 
mUl/mL); (3) Insulin 5 mUl/mL and GDC–G326 3 μM; and 
(4) GDC–G326 3 μM. Of note, the tissue was not perfused, 
but superfused and under ongoing hypoxia whilst being 
transferred to the laboratory.
mPTP opening assay
The sensitivity of the mPTP to opening was assayed using a 
well-characterized cellular model of reactive oxygen species 
(ROS)-mediated mPTP opening [6]. Briefly, tetra-methyl 
rhodamine methyl ester (TMRM, from S Sigma-Aldrich, 
UK), a lipophilic cation which is very positively charged, 
accumulates selectively into the negatively charged mito-
chondrial matrix. At high concentration (12 μM), TMRM 
becomes quenched at the mitochondria. Constant confocal 
laser stimulation (at 543 nm wavelength) of TMRM gener-
ates ROS within the mitochondria thereby simulating mito-
chondrial ROS production during reperfusion. After a few 
minutes of continual confocal laser scanning, ROS induces 
mPTP opening, producing a drop in mitochondrial mem-
brane potential and resulting in the dequenching of TMRM, 
which in turn relocates to the cytoplasm [7]. This leak of 
the dye from the mitochondria to the cytosol increases the 
detectable fluorescent signal, which is used as surrogate 
marker for mPTP opening.
Adult mouse ventricular cardiomyocytes were isolated as 
previously described. Live cardiomyocytes were incubated 
with the fluorescent dye TMRM at 12 μM for 15 min in 
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Hepes-based recording buffer (NaCl156 mM, KCl 3 mM, 
 MgSO4.7H20 2  mM,  K2HPO4 1.25  mM,  CaCl2 2  mM, 
HEPES 10 mM, and d-glucose 10 mM; pH 7.4), then washed 
and randomly treated for 15 min into the following groups: 
(1) vehicle control; (2) insulin 5 mU/mL; (3) insulin 5 mU/
mL with GDC–G326 3 μM; and (4) GDC–G326 3 μM alone. 
Once washed for a second time, mouse cardiomyocytes were 
stimulated with laser illumination and imaged using con-
focal microscopy. The time to reach half peak signal was 
recorded in seconds and compared across groups. A total of 
19 ± 2 cardiomyocytes were analyzed for each intervention 
in each experiment (n = 8 mice).
Statistical analyses
Normal distribution of each data subset was tested using 
graphical methods and the Kolmogorov–Smirnov method. 
All values are presented as mean ± standard error of the 
mean. Comparisons between protein content of PI3Kα were 
performed using the unpaired t test or the Mann–Whitney 
test depending on the normal distribution of the data. All 
other continuous data were compared either using one-way 
analysis of variance if normally distributed or using the non-
parametric Kruskal–Wallis test if highly skewed distributed. 
P values for post hoc pairwise comparisons to the control 
group were adjusted using the Dunnett’s test if normally 
distributed or the Dunn’s test if non-normally distributed. A 
P value of less than 0.05 was considered statistically signifi-
cant. STATA software version 13.1 (Stata Corp, College Sta-
tion, TX, USA), SPSS Statistics version 21 (IBM, Armonk, 
NY, USA), and GraphPad Prism version 6.00 (GraphPad 
Software, La Jolla, CA, USA) were used to perform the 
analyses and produce the graphs. The results were reported 
according to the ARRIVE guidelines for reporting animal 
research [24].
Results
PI3Kα expression levels in cardiac tissue and cells
We first quantified PI3Kα protein expression in mouse and 
human heart tissue relative to recombinant PI3Kα standards 
(Fig. 1a). In the tissue, PI3Kα was found to be expressed at a 
similar level of total protein in both mouse and human heart, 
respectively (0.20 ± 0.03 and 0.21 ± 0.04 ng per μg heart 
protein, P = 0.76). At a cellular level, PI3Kα was 2.5fold 
more highly expressed in endothelial cells than in cardiomy-
ocytes (Fig. 1b). PI3Kα mRNA expression in mouse cardiac 
tissue (Fig. 1c, d) also suggests a greater expression of this 
isoform in endothelial cells compared to cardiomyocytes.
Selection of IPC protocol and PI3Kα inhibitor dose
To select an IPC protocol able to confer protection in an 
ex vivo model, we compared preconditioning strategies of 
1 cycle vs. 4 cycles. IPC 4 cycles demonstrated a significant 
reduction of myocardial infarct size (IS) compared to control 
group (21.1 ± 3.2 vs. 38.0 ± 1.7%, P = 0.006), whilst IPC 
1 cycle was not effective (34.3 ± 4.6, P = 0.67 compared 
to control group) (Fig. 2a). PI3K pathway activation, as 
assessed by the levels of phospho-serine473 and phospho-
threonine308 Akt levels, was increased after IPC 4 cycles 
compared to the control group, whilst Akt phosphorylation 
after IPC 1 cycle was not significantly increased (Fig. 2b–d).
To identify appropriate doses of PI3Kα inhibitors, we 
generated a dose–response curve using GDC–G326 and 
BYL719, two distinct PI3Kα-selective inhibitors, in the con-
text of stimulation with insulin, a known canonical activator 
of PI3Kα. These experiments indicated that 3 µM of each 
drug is sufficient to inhibit Akt(Ser473) and Akt(Thr308) 
phosphorylation induced by insulin (Fig. 2e–g). Hence, 
these concentrations were used to evaluate the role of PI3Kα 
in cardioprotection in subsequent experiments.
PI3Kα mediates protection by IPC against myocardial 
IRI
In the Langendorff-perfused, ex vivo mouse heart model, 
IPC reduced IS compared to control (49 ± 4 vs. 23 ± 2%, 
P < 0.001). This protection was unaffected by GDC–G326 
(26 ± 3%) or BYL719 (25 ± 3%) when administered only 
during IPC, despite Akt phosphorylation being inhibited 
(Figs. 3a, b, 4b). Importantly, these two structurally distinct 
inhibitors did abrogate protection when given at reperfu-
sion (GDC–G326: 50 ± 3%; BYL719: 47 ± 4%) and also 
blocked Akt phosphorylation (Figs. 3c, d, 4c), revealing a 
distinct role for the PI3Kα isoform during the early moments 
of reperfusion. Neither drug affected IS on its own.
These experiments were confirmed in an in vivo setting 
using GDC–G326, which was found to block IPC protec-
tion when administered at reperfusion (control 56 ± 5 vs. 
IPC + GDC–G326 60 ± 5%, P = 0.93, and IPC alone was 
29 ± 6%, P = 0.003) (Fig. 3e, f).
Insulin, a canonical activator of PI3Kα, is protective 
at reperfusion
Having established that PI3Kα is necessary to mediate 
the protection provided by preconditioning, we evaluated 
whether activation of PI3Kα at reperfusion would be suf-
ficient to elicit a protective effect. When administered 
at reperfusion, the canonical PI3Kα activator (insulin) 
reduced myocardial IS compared to control (25 ± 2 vs. 
55 ± 4%, P < 0.001) and this protection was abolished by 
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GDC–G326 (48 ± 3%, P = 0.687 compared to control), as 
depicted in Fig. 5a. The degree of protection was similar 
to that attained using bradykinin as a pharmacological 
positive control. Accordingly, Akt was activated by insu-
lin and blocked when GDC–G326 was co-administered 
at reperfusion following a protocol of IRI (Fig. 5b–d).
PI3Kα can be activated in mouse cardiomyocytes, 
endothelial cells, and atrial human tissue
Having established a central role of PI3Kα in cardiopro-
tection, we aimed to determine whether insulin stimulated 
PI3Kα activation only in cardiomyocytes or also cardiac 
endothelial cells. Our results show that Akt is activated in 
both cell types in response to insulin and this effect was 
lost upon co-administration with GDC–G326 (Fig. 6a, 
b). Furthermore, to assess the translation potential of 
our findings, we collected human right atrial appendage 
samples and tested whether the PI3Kα pathway could be 
stimulated (patient baseline characteristics are outlined in 
Table 1). Human tissue was shown to respond to insulin 
with PI3Kα-dependent phosphorylation of Akt, although 
the fold increase was lower due to a higher basal activity 
(Fig. 6c, d).
Fig. 1  PI3Kα protein and 
mRNA levels. PI3Kα pro-
tein expression in mouse and 
human cardiac tissue (a) and 
cardiomyocytes and endothelial 
cells (b). PI3Kα values were 
extrapolated using a lineal 
regression from three differ-
ent amounts of recombinant 
PI3Kα (1, 3, and 10 ng). Results 
are presented as mean ± SEM 
and expressed as ng of PI3Kα 
per μg of heart protein. PI3Kα 
mRNA expression in mouse 
cardiac tissue (c, d, with and 
without DAPI-stained nuclei in 
blue, respectively). RNAScope, 
a high sensitivity method of 
in situ hybridization, was used 
to specifically detect PI3Kalpha 
mRNA expression in mouse 
heart sections. Bright dots 
represent PI3Kalpha mRNA. 
A few dots are visible in the 
cytosol of cardiomyocytes (vis-
ible from their green autofluo-
rescent background), but there 
are proportionally many more 
dots in the endothelial cells of 
capillaries running alongside 
them, as indicated by arrow 
heads, and in endothelial cells 
lining larger vessels (demar-
cated by dotted lines). Scale bar 
20 μm. *P < 0.05, **P < 0.01, 
***P < 0.001, and ns non-
significant
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PI3Kα activation delays the mPTP opening
The sensitivity of the mPTP to opening was assayed in adult 
mouse ventricular cardiomyocytes using a well-character-
ized cellular model of ROS-mediated mPTP opening. In the 
presence of insulin, the time taken to induce mPTP opening 
(a surrogate for cell death) was significantly increased com-
pared to control (571 ± 30 vs. 459 ± 25, P < 0.013), whilst 
treatment with GDC–G326 abrogated this effect (455 ± 24 s, 
P = 0.999) (Fig. 6e), GDC–G326 having no effect on its 
own (467 ± 25 s, P = 0.993). These results suggest that 
PI3Kα signalling promotes cardiomyocyte survival through 
the inhibition of the end-effector, mPTP.
Discussion
Summary of findings
Using a targeted pharmacological approach, we show that 
PI3Kα activity is required during the early reperfusion phase 
to reduce myocardial infarct size, as demonstrated with IPC 
in both ex vivo and in vivo myocardial infarction models. In 
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addition, the exogenous administration of insulin, a canoni-
cal activator PI3Kα, was also shown to confer cardiopro-
tection, further demonstrating the importance of PI3Kα 
in this setting. The potential translational ability of PI3Kα 
was demonstrated by showing it to be similarly expressed 
in both human and mouse heart tissues and to respond to 
insulin in both tissues. At a cellular level, PI3Kα expression 
was shown to be higher in mouse cardiac endothelial cells 
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compared to cardiomyocytes, with its effect being mediated 
through the inhibition of mPTP opening.
Role of PI3Kα and other isoforms in IPC
The RISK pathway has been widely demonstrated to be 
involved in the protection against IRI conferred by both 
mechanical and pharmacological conditioning strategies 
carried out at reperfusion [13, 14, 54]. PI3K is a component 
of this signalling cascade and, therefore, is an important 
therapeutic target. Nonetheless, little is known about the role 
of the distinct PI3K isoforms in IRI setting. Using a phar-
macological approach, we have demonstrated that PI3Kα 
mediates the IPC-induced protective effect during the early 
moments of reperfusion, but appears not to have a role dur-
ing the application of the IPC protocol. This is surprising as 
Akt phosphorylation was abolished at both timepoints fol-
lowing PI3Kα inhibition. Assuming that the specific-PI3Kα 
inhibitors do not block other isoforms, it might be speculated 
that PI3Kα-induced Akt phosphorylation is not relevant to 
promote myocardial salvage during the IPC protocol. The 
increase of PIP3 following PI3K activation by IPC would 
not only translate in Akt phosphorylation (which might be 
irrelevant in this phase) [36], but in other unrevealed cellular 
mechanisms.
Consistent with our results, transgenic experiments have 
indicated that PI3Kα improves left ventricular function in 
a mouse myocardial infarction-induced heart failure model 
[28], as well as improving contractile dysfunction [30, 31] 
and preventing exercise-induced cardiomyopathies [32].
In the heart, the most highly expressed PI3K isoforms are 
PI3Kα and PI3Kβ [10], although little is known about their 
absolute and relative amounts. PI3Kα can be exclusively 
activated by tyrosine kinase receptor, whilst there is compel-
ling evidence demonstrating that both tyrosine kinase recep-
tor and G protein-coupled receptors (GPCR) can engage 
PI3Kβ [4, 11], which is in turn involved in Akt activation 
in platelets, and in thrombus formation and maintenance, 
but without known evidence on this involvement in IRI and 
cardioprotection. PI3Kγ signals downstream of GPCRs. As 
IPC is mostly mediated by GPCRs ligands, this PI3K iso-
form has raised interest in a cardiac context. Although not 
examined in this paper, PI3Kγ has been postulated to be a 
mediator of the protection afforded by IPC, as IPC-induced 
protection is lost both in transgenic mice with cardiac-spe-
cific overexpression of a catalytically inactive mutant PI3Kγ 
[49] and knockout mice (PI3Kγ−/−) [2]. In contrast to genetic 
approaches, pharmacological strategies are able to provide 
novel information by permitting temporally restricted inhi-
bition during either the application of the IPC protocol or 
at reperfusion. Moreover, it is not always clear whether the 
molecular signalling alterations of genetically modified ani-
mal models can be directly attributed to the targeted gene 
or to the activation of compensatory signalling pathways. 
Taken together, we might speculate that PI3Kγ, which 
involves GPCR-ligand activation, may be involved in the 
protection elicited by IPC during the IPC protocol, whilst 
PI3Kα, which involves tyrosine kinase activation, is required 
at reperfusion for IPC to protect against IRI.
Pharmacological PI3Kα activation at reperfusion
In our study, we have used insulin as the PI3Kα canonical 
activator [8, 27]. There is a wealth of evidence demonstrat-
ing that insulin mimics the IPC stimulus by activating the 
RISK pathway, therefore, conferring protection against IRI 
both in vitro and in vivo through the PI3K–Akt kinase cas-
cade [22, 23, 46]. In the swine model, insulin postcondi-
tioning has recently been shown to reduce myocardial IS in 
a dose-dependent manner [46]. Not surprisingly, we found 
insulin to be protective in our models, which we confirm to 
specifically be mediated via PI3Kα. Under the hypothesis 
of protecting the heart from energy depletion [47], insulin 
has already been tested as a cardioprototective therapy in 
the clinical setting, with overall disappointing results [34], 
although in the subgroup of patients presenting with STEMI 
in the Immediate Myocardial Metabolic Enhancement Dur-
ing Initial Assessment and Treatment in Emergency Care 
(IMMEDIATE) trial, the administration of glucose–insu-
lin–potassium therapy significantly reduced cardiac mag-
netic resonance-evaluated infarct size [42]. The fact that 
we have identified PI3Kα to mediate the insulin-induced 
protective effect can move the focus from the use of insulin 
(a “dirty” drug with many side effects, such as hypogly-
cemia, hypokalemia, and catecholamine elevation) to the 
development of pharmacological agents specifically target-
ing PI3Kα. We are not proposing insulin to come to the fore 
again, but to take advantage of the overwhelming evidence 
demonstrating its protective effect to further improve our 
ability to target its downstream signalling.
With regard to the end-effector mechanism mediating the 
PI3Kα effect, we used the ROS-mediated mPTP model to 
Fig. 4  Impact of PI3Kα inhibition on Akt phosphorylation during 
the IPC protocol and at reperfusion. a Overview of protocols per-
formed to assess Akt phosphorylation using western blot analysis. 
Black boxes represent periods of ischemia, white boxes represent 
periods of perfusion with Krebs–Henseleit buffer at 80  mmHg, and 
coloured boxes represent the perfusion of a given drug (turquoise for 
G326 and salmon for BYL719). Arrows represent the moment, where 
samples were collected (in red, all samples collected after IPC pro-
tocol; in green, all samples collected at reperfusion). b Akt activity 
measured after IPC in the presence or absence of PI3Kα inhibitors 
(i.e., during the IPC protocol) and c Akt activity measured at reper-
fusion following PI3Kα inhibition during either IPC protocol phase 
only (“drug + IPC”), or at reperfusion (“IPC + drug”). IPC ischemic 
preconditioning
◂
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confirm the involvement of the mitochondria in the insu-
lin-induced PI3Kα activation. Using broad-spectrum PI3K 
inhibitors, our group had previously linked the activation of 
the PI3K–Akt pro-survival kinase pathway through insulin 
with the inhibition of the mPTP [7]. Our pharmacologi-
cal approach used in cells further suggests that the effect 
of insulin on the mPTP opening is mediated by PI3Kα, 
although we lack specific data linking PI3Kα and mPTP in 
preconditioned cardiomyocytes.
PI3Kα expression and activation in cells and tissues
PI3Kα is expressed in a similar proportion in both mouse 
heart and human atrial tissue. Moreover, PI3Kα activity can 
be pharmacologically modulated in both tissues, as dem-
onstrated using its canonical activator and specific inhibi-
tor. These observations set PI3Kα as a potential target with 
translational value in cardioprotection. To our knowledge, 
this is the first study reporting comparisons in PI3Kα pro-
tein levels between mouse and human heart tissue. Differ-
ences in protein levels between cardiomyocytes and mouse 
cardiac endothelial cells have also been reported, although 
caution should be taken when comparing primary isolated 
with immortalized cultured cells. Our qualitative results on 
PI3Kα mRNA expression in mouse heart tissue also sug-
gest a greater expression of the isoform in endothelial cells 
compared to cardiomyocytes in culture. Although cardio-
myocytes have become central to recapitulate reductionist 
models of preconditioning against IRI through hypoxia/reox-
ygenation experiments, it remains largely unknown to what 
extent other cardiac cells can contribute in the conditioning 
phenomena on top of cardiomyocytes. Some advocate that 
the endothelium might have a relevant role in cardioprotec-
tion due to both its optimal situation to interact with blood 
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signals and its paracrine capacity/ability, i.e., nitric oxide has 
been long associated with ischaemic conditioning through 
the role of eNOS (the endothelial isoform of nitric oxide 
synthase) [3]. Besides being a provider of protective triggers 
and mediators to cardiomyocytes, there is also the possibility 
for the endothelium to be a target itself for cardioprotection, 
i.e., preserving microvascular function. Unfortunately, there 
is little evidence of the specific role of PI3Kα to provide 
cardioprotection in non-cardiomyocyte cells and this issue 
needs to be adequately addressed in further studies.
Translational outlook
The translational perspective of our results is highlighted 
by the observation that PI3Kα is expressed in human heart 
tissue and can be stimulated by its canonical activator insu-
lin, although we did not performed experiments addressing 
the cardioprotective effect of insulin in the human tissue. 
Given that PI3Kα is involved in the cardioprotection ren-
dered by IPC and insulin at reperfusion, future therapeutic 
strategies could more specifically target this α isoform of 
PI3K to enhance its IS-limiting effect in an acute post-myo-
cardial infarction setting, and avoiding the PI3K-independ-
ent effects on the metabolism that limits the use of insulin. 
Thus, further studies with specific PI3Kα activators should 
be tested in both small- and large-animal models, before 
being eventually translated in STEMI patients who undergo 
coronary revascularization. These studies should take into 
account the current challenges to translate cardioprotective 
therapies [17, 20, 41].
Strengths and limitations
To study the activation of the PI3Kα isoform in IPC, we 
used a pharmacological approach in several experimental 
models (ex vivo, in vivo, and mPTP assay). Although it 
could be argued that genetically modified animal models 
could also have been used to further examine the role of 
PI3Kα, this would not have been possible due to the fact 
that chronic deletion of the protein would not allow us to 
focus on specific phases of the conditioning process, i.e., 
before ischemia and at reperfusion. To overcome the risk of 
off-target effects with inhibitors, we used two structurally 
unrelated inhibitors and observed the same results.
Human heart tissue was obtained from the right atrium. 
Despite carefully selecting patients without arrhythmias, we 
appreciate that left ventricular tissue would better represent 
the human model, but this was not possible to obtain. More-
over, only an insulin-dependent activation of PI3Kα was 
shown in the human tissue, leaving unanswered the question 
on whether PI3Kα mediates the IPC-protective effect. Cau-
tion should also be taken when extrapolating the results on 
an immortalized cell line (mouse cardiac endothelial cells) 
to a more physiological setting.
Several considerations regarding the RISK pathway need 
to be taken into account regarding the translational value of 
our results. First, most of the experimental studies involving 
the RISK pathway as a cardioprotective pathway have been 
performed in small rodent models of IRI, whereas its central 
role in large animals is less well established [9, 44]. Sec-
ond, we focused on classic IPC, not remote preconditioning. 
Whilst the link between IPC and RISK activation has been 
demonstrated in humans [43], there is less certainty about 
the role of the RISK pathway in remote preconditioning in 
both large-animal models [45] and humans [19].
Conclusions
PI3Kα activity is required during the early reperfusion phase 
to reduce myocardial infarct size. The development of drugs 
enhancing PI3Kα activity at reperfusion could potentially 
promote myocardial salvage in patients undergoing acute 
myocardial infarction.
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